当前位置: 首页 >> 检索结果
3817. Oral emergency contraception with levonorgestrel plus piroxicam: a randomised double-blind placebo-controlled trial.
作者: Raymond Hang Wun Li.;Sue Seen Tsing Lo.;Kristina Gemzell-Danielsson.;Carol Ho Yi Fong.;Pak Chung Ho.;Ernest Hung Yu Ng.
来源: Lancet. 2023年402卷10405期851-858页
Levonorgestrel, a standard drug for emergency contraception (EC), is not effective if administered post-ovulation. A cyclo-oxygenase inhibitor could contribute synergistic effects. We investigated whether a single 40 mg oral dose of piroxicam as co-treatment with levonorgestrel improved emergency contraceptive efficacy.
3818. Participation rate and yield of two home-based screening methods to detect increased albuminuria in the general population in the Netherlands (THOMAS): a prospective, randomised, open-label implementation study.
作者: Dominique van Mil.;Lyanne M Kieneker.;Birgitte Evers-Roeten.;Marc H M Thelen.;Hanne de Vries.;Marc H Hemmelder.;Annemiek Dorgelo.;Ronald W van Etten.;Hiddo J L Heerspink.;Ron T Gansevoort.
来源: Lancet. 2023年402卷10407期1052-1064页
Chronic kidney disease (CKD) has a rising global prevalence and is expected to become the fifth leading cause of death by 2030. Increased albuminuria defines the early stages of CKD and is among the strongest risk factors for progressive CKD and cardiovascular disease. The value of population screening for albuminuria to detect CKD in an early phase has yet to be studied. We aimed to evaluate the effectiveness of two home-based albuminuria population screening methods.
3819. Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial.
作者: Richard Lafayette.;Jens Kristensen.;Andrew Stone.;Jürgen Floege.;Vladimir Tesař.;Hernán Trimarchi.;Hong Zhang.;Necmi Eren.;Alexander Paliege.;Heather N Reich.;Brad H Rovin.;Jonathan Barratt.; .
来源: Lancet. 2023年402卷10405期859-870页
IgA nephropathy is a chronic immune-mediated kidney disease and a major cause of kidney failure worldwide. The gut mucosal immune system is implicated in its pathogenesis, and Nefecon is a novel, oral, targeted-release formulation of budesonide designed to act at the gut mucosal level. We present findings from the 2-year, phase 3 NefIgArd trial of Nefecon in patients with IgA nephropathy.
3820. Omicron neutralisation: RBD-dimer booster versus BF.7 and BA.5.2 breakthrough infection.
作者: Lianpan Dai.;Huixin Duan.;Xueyuan Liu.;Huan Zhou.;Minrun Duan.;Yaling An.;Linfeng Yuan.;Xin Zhao.;Kun Xu.;Qiang Wu.;George F Gao.
来源: Lancet. 2023年402卷10403期687-689页 |